# DESTINY-LUNG02 (NCT04644237)

> Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04644237
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Daiichi Sankyo
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Trastuzumab deruxtecan
- Enrollment: 152
- Primary outcome: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer

## Commentary we found

- Podcasts: 48
- YouTube: 34
- X threads: 20

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=destiny-lung02-nct04644237

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04644237", "email": "<work email>"}; the inbox owner confirms by the emailed link.